Philip Hart, PhD
Vice President, New York
What do you like about Deallus?
The opportunity to learn from folks at every level of our organization is something I’ve really enjoyed at Deallus. I always feel there are open ears for good ideas, and there is great freedom for you as an individual to use your time wisely.
First and foremost, for client work, but – if you’re efficient – then you can also get involved in optimizing our process. This is at every level in our organization, and in areas that match your interest and skillset. And, while a company can always stand to recognize its people more, I think we do a good job of recognizing those who do get involved with the bones of our business and contribute growth both within and outside of their work with clients.
Beyond that, I feel like we have the wonderful ability to talk to market stakeholders in ways that pharmaceutical companies simply can’t. Through this mandate – primary research – we get profoundly interesting exposures to industry experts with cutting-edge perspectives. That is exceptionally rewarding.
Author
Communicating with impact. I’m skilled at boiling down information to what people absolutely need to know and keeping them engaged. I take a lot of pride in delivery of insight – whether that’s verbal, visual, or written. I’m motivated by producing high-quality outcomes and the delight that this brings to clients. If I can knock someone’s socks off because what I’ve produced for them is better than what they’ve ever seen before, then I feel successful.
![Philip-Hart-Deallus-Senior-Principal Philip Hart, Deallus Principal, New York](https://www.deallus.com/wp-content/uploads/2019/11/Philip-Hart-Deallus-Senior-Principal.png)
Background and experience
Nearly 14 years life science consulting delivering impact across clients’ competitive readiness, commercial development and access strategy
Worked with all but one of the world’s commercial-stage CAR T players, and many of the world’s leading oncology franchises
Extensive experience across EU and US markets
Therapy area expertise
Cell and gene therapy – including CAR-T
Non-Hodgkin’s Lymphomas (MM)
Multiple myeloma (MM)
Breast Cancer
Prostate Cancer (PCa)
NSCLC
Anemia, iron deficiency anemia (IDA), and iron deficiency (ID)
Hereditary angioedema (HAE)
Multiple sclerosis (MS)
Spinal muscular atrophy (SMA)
Major depressive disorder (MDD)
Friedreich’s ataxia (FA)
Bladder cancer